+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 657 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.

Age: 18Years +All GendersPhase 3
126 locations
E

Actively Recruiting

This research aims to evaluate the efficacy and safety of rilzabrutinib in adults diagnosed with active Immunoglobulin G4-related disease IgG4-RD. It is a Phase 3, randomized, double-blind, placebo-controlled study that will measure the time to clinical disease flare and other important efficacy and safety outcomes over a 52-week treatment period. The study includes adult participants aged 18 and older who have a confirmed diagnosis of IgG4-RD and active disease in at least one organ. Participants will be randomly assigned to receive either rilzabrutinib tablets or a placebo, both taken orally, over a 52-week double-blind treatment period. The study also includes a screening period of 4 to 6 weeks before treatment, followed by a 2-week follow-up after the treatment phase. An optional open-label extension lasting 108 weeks is available for participants who complete the main study. The total study duration may extend up to 60 weeks for the main phases. Throughout the study, participants will attend up to 16 visits during the main treatment period and additional visits if they join the extension phase. Researchers will monitor disease activity and flare rates using clinical assessments, imaging procedures such as CT, MRI, PET, or ultrasound, laboratory tests, ECGs, and safety evaluations including adverse event monitoring. Outcomes include flare-free rates, disease activity scores, glucocorticoid use, and safety parameters, with follow-up continuing beyond the treatment phase to assess long-term effects.

Age: 18Years +All GendersPhase 3
95 locations
E

Actively Recruiting

Researchers are investigating new treatments for advanced renal cell carcinoma RCC, a type of kidney cancer. This study compares a standard targeted therapy called belzutifan with a combination of belzutifan and another targeted therapy, zanzalintinib. The goal is to find out if adding zanzalintinib helps people with advanced RCC live longer and without their cancer worsening compared to belzutifan alone. Participants will be randomly assigned to one of two groups. One group will take 120 mg of belzutifan orally plus 60 mg of zanzalintinib once daily for about 24 months. The other group will take 120 mg of belzutifan plus a placebo matching zanzalintinib once daily for the same period. Both treatments are given as tablets taken by mouth. During the study, participants will have regular evaluations to monitor their cancers status, side effects, and quality of life. Researchers will use specific measures such as progression-free survival PFS and overall survival OS over up to 50 months. Other assessments include tumor response, duration of response, adverse events, and changes in health questionnaires related to physical function and symptoms. Safety and treatment effects will be carefully tracked throughout the study.

Age: 18Years +All GendersPhase 3
106 locations
E

Actively Recruiting

Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.

Age: 18Years +All GendersPhase 3
221 locations
E

Actively Recruiting

Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.

Age: 18Years +All GendersPhase 3
245 locations
E

Actively Recruiting

Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.

Age: 18Years +MALEPhase 3
303 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ifinatamab deruxtecan I-DXd, alone or combined with other treatments, in people with metastatic castration-resistant prostate cancer mCRPC. This study aims to understand how well participants tolerate the treatment, find a safe dose level for combination therapies, and monitor prostate-specific antigen PSA levels during treatment. The study is part of a larger master screening protocol and includes participants with advanced prostate cancer. Participants may receive one of several treatment plans docetaxel chemotherapy every three weeks for up to 10 cycles I-DXd alone every three weeks until side effects, disease progression, death, or withdrawal I-DXd combined with opevesostat after dose escalation until stopping criteria are met or I-DXd combined with an androgen receptor pathway inhibitor abiraterone or enzalutamide under similar conditions. Before each I-DXd dose, participants take medications to prevent nausea and vomiting. During the study, participants will have regular assessments including monitoring for treatment side effects, PSA response, and disease progression. Researchers will track dose-limiting toxicities, adverse events, and reasons for stopping treatment over periods ranging from about three weeks to over four years. Secondary measures include overall survival, radiographic progression-free survival, and time to pain progression. Participation may last several years, with ongoing safety and effectiveness evaluations carried out throughout this time.

Age: 18Years +All GendersPhase 1Phase 2
82 locations
E

Actively Recruiting

Researchers are investigating new treatments for people with high-risk non-muscle invasive bladder cancer HR NMIBC, a type of bladder cancer that affects the inner lining and has not spread to the muscle. This condition includes carcinoma in situ CIS, a flat cancer limited to the bladders surface. The study aims to find out if adding intismeran autogene to the standard Bacillus Calmette-Guerin BCG treatment can help patients live longer without their cancer growing, spreading, or returning. Participants receive either intismeran autogene combined with BCG or BCG alone. Intismeran autogene is given as a 1 mg intramuscular injection every 3 weeks for nine doses. BCG is administered as a 50 mg intravesicular instillation once weekly for 6 weeks initially, then during weeks 13-15, 25-27, 49-51, and 73-75. Some participants receive only intismeran autogene. The study follows these treatments in separate groups to compare outcomes. During the study, participants undergo assessments over up to approximately five years to measure event-free survival, recurrence-free survival, disease-specific survival, overall survival, and other health outcomes. Researchers track cancer response, monitor adverse events, and evaluate how long participants remain cancer-free. Regular visits and tests help monitor safety and treatment effects throughout the study period.

Age: 18Years +All GendersPhase 2
89 locations
S

Actively Recruiting

Researchers are investigating whether MK-1084, a targeted therapy, can treat advanced or metastatic non-squamous non-small cell lung cancer NSCLC with KRAS G12C mutations. This study aims to evaluate the safety of MK-1084 when taken with other treatments and to see how many participants experience tumor shrinkage or disappearance. The trial is a phase 1b2 umbrella study focusing on previously treated participants with this specific lung cancer type. Participants receive MK-1084 combined with either Patritumab deruxtecan HER3-DXd or Sacituzumab tirumotecan Sac-TMT until treatment is stopped due to side effects, adverse events, or investigator decision. An arm with MK-1084 plus Cetuximab was discontinued. MK-1084 is given orally, and the other drugs are administered by intravenous infusion. Rescue medications for nausea and vomiting may be given as needed. Throughout the study, participants undergo evaluations for dose-limiting toxicities, adverse events, and treatment discontinuations due to side effects, monitored up to approximately 63 months. Researchers also assess tumor response rates and progression-free survival. Biomarker analysis is performed using tumor tissue or circulating tumor DNA. The trial follows participants until the study completion date in 2032, with ongoing safety and effectiveness monitoring.

Age: 18Years +All GendersPhase 1Phase 2
29 locations
S

Actively Recruiting

Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.

Age: 18Years +All GendersPhase 3
227 locations

1-10 of 657

1